Cinven is reviewing strategic options for laboratory-services company Synlab International GmbH including a potential sale, people with knowledge of the matter said.
The private equity firm has been speaking with potential advisers and could start a sale process early next year, the people said, asking not to be identified because the information is private. Cinven plans to seek a valuation of about 5.5 billion euros ($6 billion) including debt for Augsburg, Germany-based Synlab, one of the people said.
A sale of Synlab would likely attract other private equity firms, the people said. No final decision has been made, and Cinven could elect to keep the business, the people said. A spokeswoman for Cinven declined to comment, while Synlab didn’t answer phone calls seeking comment.
Cinven first invested in Synlab in June 2015, buying a majority stake from fellow private equity firm BC Partners for about 1.7 billion euros, Bloomberg News reported at the time. It combined the business with Labco SA, which it agreed to buy earlier that year for 1.2 billion euros.
Synlab, led by Chief Executive Officer Mathieu Floreani, also counts Novo A/S and Ontario Teachers’ Pension Plan as minority investors, according to its website. It operates across more than 40 countries, handling more than 500 million clinical tests annually, according to Synlab’s website.
Cinven also owns stakes in retailer Kurt Geiger and German drugmaker Stada Arzneimittel AG, according to its website.
The sale plan comes at a time when Cinven’s rival Apax Partners is also weighing a sale of diagnostic services business Unilabs. The buyout firm is working with advisers at Rothschild & Co. to look at options for the business, people familiar with the matter said last week.
Source: Bloomberg
Can’t stop reading? Read more
Blackstone Becomes First $1tr Private Equity Manager
Passing that milestone puts the firm in the same league as mutual fund behemoths and banking giants. Private equity firms have sought to join a special club: managing $1 trillion in assets, a milestone that would put them in the same league as mutual fund behemoths...
KKR to buy chemical maker Chase in $1.3bn deal
KKR & Co said on Friday it would buy chemical maker Chase in an all-cash deal valued at about $1.3 billion including debt, to help the private equity firm bolster its holdings in the chemical specialty sector. Under the deal terms, KKR will buy all outstanding...
CVC raises €26bn for its ninth Europe/Americas Private Equity Fund
CVC is pleased to announce the successful close of CVC Capital Partners IX (“Fund IX”) at €26 billion, exceeding its €25bn target. Its predecessor, CVC Capital Partners VIII, was raised in 2020 and closed at € 22.3bn. CVC launched Fund IX in January 2023 and has...